Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

Robert A. Hodgson(Merck & Co., Inc., Rahway, NJ, USA (United States)), John C. Hunter, Rosalia Bertorelli(San Raffaele University of Rome), Jean E. Lachowicz, Geoffrey B. Varty(Institute of Neurobiology), Eric M. Parker(University of New Hampshire), Elisa Nicolussi(San Raffaele University of Rome), Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mary Cohen-Williams, A Forlani(San Raffaele University of Rome), B Neustadt, Silva Fredduzzi(San Raffaele University of Rome), Francesco Impagnatiello(Tethys Research Institute), Leonard E. Parra, Ying Zhai, Angelo Reggiani(San Raffaele University of Rome), Carolyn Foster, Guy A. Higgins
Journal of Pharmacology and Experimental Therapeutics
March 31, 2009
Cited by 149


Related Papers